Kathleen LaPorte Granted Stock Options in Q32 Bio Inc.

Kathleen LaPorte, a director of Q32 Bio Inc., was granted 53,521 stock options on October 23, 2025. The options, which are exercisable at $2.80 per share, will vest and become exercisable in full upon the earlier of October 23, 2026, or the date of the issuer's next annual meeting of stockholders, subject to LaPorte's continued service on the vesting date. The options expire on October 22, 2035. This transaction was reported in a Form 4 filing with the SEC.